Objectives To compare two measures of systemic lupus erythematosus (SLE) response: the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept ...

Objective Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disorder with no reliable serum biomarkers currently available other than autoantibodies. Methods In the present study, ...

Objective Patients with SLE frequently have debilitating fatigue and reduced physical activity. Intermuscular adipose tissue (IMAT) accumulation is associated with reduced physical exercise capacity.

Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective ...

Objective Accelerated atherosclerosis remains the major cause of late death (after 5 years) in SLE. Yet, the ‘traditional’ cardiovascular risk equations (such as Framingham) consistently underestimate ...

In the past decade, the world of publishing has undergone rapid changes with the proliferation of online journals and the advances of the open access movement. Consequently, the roles of authors and ...

Direct oral anticoagulants (DOACs) are the standard of care for anticoagulation following a first episode of venous thromboembolism (VTE) in the general population, however, special considerations ...

With its first description published in 1976 the bimodal mortality pattern in systemic lupus erythematosus (SLE) described early mortality as usually being due to lupus disease itself or infection, ...

Systemic lupus erythematosus (SLE) predominantly affects young individuals with potential to be productive members of society. SLE also significantly increases healthcare utilization with higher ...

Objective SLE is an autoimmune disease characterised by persistent inflammation and autoantibody production. Genetic predisposition and environmental factors such as a high-fat diet (HFD) may ...

Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE. We reviewed established ...